Leadership Group:
Ljubica Besker-Ivasovic MD, PhD Capoclinica, Clinica S. Anna, Bellinzona Switzerland
Alex Z. Fu PhD Assistant Professor, Quantitative Health Sciences
Cleveland Clinic, Cleveland, OH USA
Amy Guo PhD Director, Health Economics & Outcomes Research, Bayer, Wayne, NJ USA
John Martin MPH, Research Manager, CareScience, Philadelphia, PA USA
Alan H. Mutnick BS, PharmD, Director, Clinical Effectiveness, Mercy Health Partners, Southwest Ohio, Cincinnati, Ohio

• Increase the adoption of clinical, economic, and quality of life/humanistic outcomes research in hospital and health system decision making.
• Understand the hospital administrators (C-suite and director levels) decision making process and key drivers to arrive the decisions.

• Identify key issues from the Hospital and Health System perspective on the use of clinical, economic, and humanistic outcomes research.
• Determine how to address these issues.
• Define good research practices / guidelines to conduct outcomes research that is readily understandable and useful to health care management.
• Recommend a reporting format(s) for outcomes research information.
• Write up the Hospital and Health System real world examples as case studies.
• Communicate these findings and promote adoption of outcomes research in health care management decisions through publications, presentations, short courses and other communication tools, such as slide sets.

1. Conduct a survey of health care managers and/or literature review to identify the key outcomes research issues from a Hospital & Health system’s perspective, including their knowledge of Pharmacoeconomics & Outcomes Research and its application to their health benefit decision-making process.
2. Analyze these findings and identified issues then make recommendations to address them.
3. Develop good practice guidelines for outcomes research from the Hospital & Health System perspectives.
4. Develop potential communication(s), such as an article, panel discussion, and health care provider’s case studies/examples to illustrate Hospital & Health System’s perspectives in outcomes research.

Meeting Presentation 2008

ARE WE BETTER OFF OR WORSE OFF WITH VALUE-BASED PURCHASING (VBP)? Peter K. Wong, PhD, MS, MBA, RPh. Vice President, Quality & Safety, Sisters of Charity of Leavenworth Health System, Lenexa, Kansas; Alan H. Mutnick, PharmD, RPh. FASHP. Director, Clinical Effectiveness, Mercy Health Partners, Southwest Ohio. ISSUE: Will VBP lead to a financial success or a financial disaster for a hospital system? HOW SHOULD NEW TECHNOLOGIES AND NEW DEVICES BE ASSESSED IN A HOSPITAL SYSTEM? Alan H. Mutnick, PharmD, RPh. FASHP, Director, Clinical Effectiveness, Mercy Health Partners, Southwest Ohio; Peter K. Wong, PhD, MS, MBA, RPh. Vice President, Quality & Safety, Sisters of Charity of Leavenworth Health System, Lenexa, Kansas; Karl Matuszewski , MS, PharmD. Senior Director, Clinical Knowledge Service, University Health System Consortium, Oak Brook, IL, USA. Issue: There currently exists a lack of sufficient long-term cost-effectiveness data on new technologies and new devices, in order for healthcare decision makers to make good decisions.   THE USE OF AN EVIDENCE-BASED PRACTICE STRATEGY TO IMPROVE QUALITY IN THE ACUTE CARE SETTING Alan H. Mutnick, PharmD, RPh. FASHP. Director, Clinical Effectiveness, Mercy Health Partners, Southwest Ohio; Peter K. Wong, PhD, MS, MBA, RPh.  Vice President, Quality & Safety, Sisters of Charity of Leavenworth Health System, Lenexa, Kansas. Issue: The availability of a growing body of high quality evidence-based practice guidelines has created exceptional opportunities to maximize the quality of care delivered to patients. However, are we utilizing the available evidence in daily practice, or is individual clinician preference still dictating practice levels? Meeting Presentation 2007 ISPOR 12th Annual International Meeting – Tuesday, May 22, 2007 2:00 PM – 3:00 PM Issue Panel Session II (IP9): Therapeutic Interchange: Are the Results Cost-Effective?   Moderator: Karl Matuszewski MS, PharmD, Senior Director, Clinical Knowledge Service University HealthSystem Consortium, Oak Brook, IL, USA Panelists: Alan H. Mutnick BS, PharmD, Assistant Director/ Clinical Pharmacy Services University of Virginia Health System, Charlottesville, VA, USA Peter K. Wong PhD, MBA, MS, Regional Director Pharmaceutical Care and Services, Mercy Health Partners, Southwest Ohio, Cincinnati, OH, USA ISSUE: “Therapeutic Interchange” has become an important tool utilized by Formulary committees to allow the exchange of therapeutic alternates as detailed with established guidelines or protocols, in order to reduce medication costs for select therapeutic drug classes.

2006 SURVEY RESULTS: Use of Pharmacoeconomics & Outcomes Research Information in Health Care Decisions